COVID‐19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS‐CoV‐2 Infection Among Target Groups in Europe, October 2024–January 2025, VEBIS Primary Care Network
Year: 2025
Type: article
Study design: Observational Study
Abstract: We estimated the effectiveness of 2024/25 COVID-19 vaccination against medically attended SARS-CoV-2 infection in Europe, among target groups. We included 3204 patients (8/139 cases vaccinated: 6%; 517/3065 controls vaccinated: 17%) from a multicentre, test-negative design study at primary care level. Vaccine effectiveness was 66% (95% CI: 34-85) overall, 73% (95% CI: 21-94) and 54% (95% CI: -3 to 83) in the first and second months post-vaccination, respectively. Overall vaccine effectiveness was 67% (95% CI: 33-86) among older adults (≥ 60 or ≥ 65 years). This relatively high COVID-19 VE (compared with previous seasons), as well as trends by time since vaccination, should be confirmed with additional data, as sample size was low.
DOI: 10.1111/irv.70120
Authors: Charlotte Laniece Delaunay, Nuno Verdasca, Susana Monge, Lisa Domegan, Noémie Sève, Silke Buda, Adam Meijer, Héloïse Lucaccioni, Miriam López Torrijos, Adele McKenna, Vincent Enouf, Ralf Dürrwald, Eline In't Velt, Mª Ángel de Valcárcel Laiglesia, Charlene Bennett, Shirley Masse, Annika Erdwiens, Mariette Hooiveld, Ivan Mlinarić, Gergő Túri, Ana Paula Rodrigues, Iván Martínez‐Baz, Mihaela Lazar, Neus Latorre‐Margalef, Vitor Borges, Marlena Kaczmarek, Sabrina Bacci, Esther Kissling, European primary care VE group
Institutions: National Institute of Health Dr. Ricardo Jorge, Instituto de Salud Carlos III, Centro Nacional de Epidemiología, Health Service Executive, Health Protection Surveillance Centre, Inserm, Sorbonne Université, Institut Pierre Louis d‘Épidémiologie et de Santé Publique, Robert Koch Institute, National Institute for Public Health and the Environment, Generalitat Valenciana, Conselleria de Sanitat Universal i Salut Pública, Institut Pasteur, Université Paris Cité, Instituto Murciano de Investigación Biosanitaria, University College Dublin, Aix-Marseille Université, Institut de Recherche pour le Développement, Unité des Virus Emergents, Hrvatski zavod za javno zdravstvo, Semmelweis University, Instituto de Salud Pública de Navarra, Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, Institutul Cantacuzino, Public Health Agency of Sweden, European Centre for Disease Prevention and Control
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,840
Funders: Irish College of General Practitioners, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, European Centre for Disease Prevention and Control, Nemzeti Kutatási Fejlesztési és Innovációs Hivatal, Robert Koch Institut, Instituto de Salud Carlos III, Rijksinstituut voor Volksgezondheid en Milieu, National Research, Development and Innovation Office
OpenAlex ID: W4410568697